Combined medical treatment using dutasteride and tamsulosin for lower urinary tract symptoms suggestive of benign prostatic hyperplasia

Bibliography

• Issa MM, Fenter TC, Black L, An assessment of the diagnosed prevalence of diseases in men 50 years of age or older. Am J Manag Care 2006;12(4 Suppl):S83-9
   Google Scholar
• Naslund MJ, Issa MM, Grogg AL, Clinical and economic outcomes in patients treated for enlarged prostate. Am J Manag Care 2006;12(4 Suppl):S111-16
   Google Scholar
• Gravas S, Melekos MD. Male lower urinary tract symptoms: how do symptoms guide our choice of treatment? Curr Opin Urol 2009;19(1):49-54
   Google Scholar
• Barry MJ, O'Leary MP. Advances in benign prostatic hyperplasia. The developmental and clinical utility of symptom scores. Urol Clin North Am 1995;22(2):299-307
   Google Scholar
• Chapple CR, Roehrborn CG. A shifted paradigm for the further understanding, evaluation, and treatment of lower urinary tract symptoms in men: focus on the bladder. Eur Urol 2006;49(4):651-8
   Google Scholar
• Abrams P, Chapple C, Khoury S, Evaluation and treatment of lower urinary tract symptoms in older men. J Urol 2009;181(4):1779-87
   Google Scholar
• American Urological Association Education and Research I. Chapter 1: AUA Guideline on the Management of Benign Prostatic Hyperplasia: Diagnosis and Treatment Recommendations. Available from: http://www.auanet.org/content/guidelines-and-quality-care/clinical-guidelines/main-reports/bph-management/chapt_1_appendix.pdf [Cited 8 August 2010]
   Google Scholar
• Mehdizadeh JL, Leach GE. Role of invasive urodynamic testing in benign prostatic hyperplasia and male lower urinary tract symptoms. Urol Clin North Am 2009;36(4):431-41, v
   Google Scholar
• Roehrborn CG. Clinical management of lower urinary tract symptoms with combined medical therapy. BJU Int 2008;102(Suppl 2):13-7
   Google Scholar
• Roehrborn CG, Schwinn DA. Alpha1-adrenergic receptors and their inhibitors in lower urinary tract symptoms and benign prostatic hyperplasia. J Urol 2004;171(3):1029-35
   Google Scholar
• Keam SJ, Scott LJ. Dutasteride: a review of its use in the management of prostate disorders. Drugs 2008;68(4):463-85
   Google Scholar
• Rittmaster RS, Norman RW, Thomas LN, Rowden G. Evidence for atrophy and apoptosis in the prostates of men given finasteride. J Clin Endocrinol Metab 1996;81(2):814-19
   Google Scholar
• Barendrecht MM, Abrams P, Schumacher H, Do alpha1-adrenoceptor antagonists improve lower urinary tract symptoms by reducing bladder outlet resistance? Neurourol Urodyn 2008;27(3):226-30
   Google Scholar
• Oelke M, Bachmann A, Descazeaud A, Conservative treatment of non-neurogenic male LUTS. 2010. Available from: http://www.uroweb.org/guidelines/online-guidelines/ [Cited 24 June 2010]
   Google Scholar
• Cantrell MA, Bream-Rouwenhorst HR, Hemerson P, Magera JS Jr. Silodosin for benign prostatic hyperplasia. Ann Pharmacother 2010;44(2):302-10
   Google Scholar
• Garimella PS, Fink HA, Macdonald R, Wilt TJ. Naftopidil for the treatment of lower urinary tract symptoms compatible with benign prostatic hyperplasia. Cochrane Database Syst Rev 2009;(4):CD007360
   Google Scholar
• Aggarwal S, Thareja S, Verma A, An overview on 5alpha-reductase inhibitors. Steroids 2010;75(2):109-53
   Google Scholar
• Faragalla J, Bremner J, Brown D, Comparative pharmacophore development for inhibitors of human and rat 5-alpha-reductase. J Mol Graph Model 2003;22(1):83-92
   Google Scholar
• Aggarwal S, Thareja S, Bhardwaj TR, Kumar M. 3D-QSAR studies on unsaturated 4-azasteroids as human 5alpha-reductase inhibitors: a self organizing molecular field analysis approach. Eur J Med Chem 2010;45(2):476-81
   Google Scholar
• Sawada K, Okada S, Golden P, 4-(1-benzoylindol-3-yl)butyric acids and FK143: novel nonsteroidal inhibitors of steroid 5 alpha-reductase (II). Chem Pharm Bull (Tokyo) 1999;47(4):481-91
   Google Scholar
• Michel MC, Korstanje C, Krauwinkel W, Kuipers M. The Pharmacokinetic Profile of Tamsulosin Oral Controlled Absorption System (OCAS®). Eur Urol Suppl 2005;4(2):15-24
   Google Scholar
• Clark RV, Hermann DJ, Cunningham GR, Marked suppression of dihydrotestosterone in men with benign prostatic hyperplasia by dutasteride, a dual 5alpha-reductase inhibitor. J Clin Endocrinol Metab 2004;89(5):2179-84
   Google Scholar
• Djavan B, Milani S, Fong YK. Dutasteride: a novel dual inhibitor of 5alpha-reductase for benign prostatic hyperplasia. Expert Opin Pharmacother 2005;6(2):311-17
   Google Scholar
• Franco-Salinas G, de la Rosette JJ, Michel MC. Pharmacokinetics and pharmacodynamics of tamsulosin in its modified-release and oral controlled absorption system formulations. Clin Pharmacokinet 2010;49(3):177-88
   Google Scholar
• Highlights of prescribing information for Flomax. Available from: http://bidocs.boehringer-ingelheim.com/BIWebAccess/ViewServlet.ser?docBase=renetnt&folderPath=/Prescribing+Information/PIs/Flomax+Caps/Flomax.pdf [Cited 21 June 2010]
   Google Scholar
• Dutasteride chemistry. Available from: http://www.dutasteride.com/dutasteride-chemistry.html [Cited 26June 2010]
   Google Scholar
• Michel MC, Korstanje C, Krauwinkel W, Comparison of vascular [alpha]1-adrenoceptor antagonism of tamsulosin in Oral Controlled Absorption System (OCAS) and Modified Release (MR) Formulations. Eur Urol Suppl 2005;4(2):45-52
   Google Scholar
• Yamada S, Kato Y, Okura T, Prediction of alpha1-adrenoceptor occupancy in the human prostate from plasma concentrations of silodosin, tamsulosin and terazosin to treat urinary obstruction in benign prostatic hyperplasia. Biol Pharm Bull 2007;30(7):1237-41
   Google Scholar
• Roehrborn C, Boyle P, Nickel J, Efficacy and safety of a dual inhibitor of 5-alpha-reductase types 1 and 2 (dutasteride) in men with benign prostatic hyperplasia. Urology 2002;60(3):434-41
   Google Scholar
• Debruyne F, Barkin J, van Erps P, Efficacy and safety of long-term treatment with the dual 5 alpha-reductase inhibitor dutasteride in men with symptomatic benign prostatic hyperplasia. Eur Urol 2004;46(4):488-94, discussion 95
   Google Scholar
• Wurzel R, Ray P, Major-Walker K, The effect of dutasteride on intraprostatic dihydrotestosterone concentrations in men with benign prostatic hyperplasia. Prostate Cancer Prostatic Dis 2007;10(2):149-54
   Google Scholar
• Andriole GL, Marberger M, Roehrborn CG. Clinical usefulness of serum prostate specific antigen for the detection of prostate cancer is preserved in men receiving the dual 5alpha-reductase inhibitor dutasteride. J Urol 2006;175(5):1657-62
   Google Scholar
• Thompson IM, Goodman PJ, Tangen CM, The influence of finasteride on the development of prostate cancer. N Engl J Med 2003;349(3):215-24
   Google Scholar
• Andriole G, Bostwick D, Brawley O, Chemoprevention of prostate cancer in men at high risk: rationale and design of the reduction by dutasteride of prostate cancer events (REDUCE) trial. J Urol 2004;172(4 Pt 1):1314-17
   PubMed Web of Science ®Google Scholar
• Andriole GL, Bostwick DG, Brawley OW, Effect of dutasteride on the risk of prostate cancer. N Engl J Med 2010;362(13):1192-202
   Google Scholar
• Barqawi AB, O'Donnell CI, Siomos VJ, Hou AH. The effect of short-term dutasteride intake in early-stage prostate cancer: analysis of 148 patients who underwent three-dimensional prostate mapping biopsy. Urology 2010 May 14. [Epub ahead of print]
   Google Scholar
• van Hoogdalem EJ, Soeishi Y, Matsushima H, Higuchi S. Disposition of the selective alpha1A-adrenoceptor antagonist tamsulosin in humans: comparison with data from interspecies scaling. J Pharm Sci 1997;86(10):1156-61
   Google Scholar
• Wolzt M, Fabrizii V, Dorner GT, Pharmacokinetics of tamsulosin in subjects with normal and varying degrees of impaired renal function: an open-label single-dose and multiple-dose study. Eur J Clin Pharmacol 1998;54(4):367-73
   Google Scholar
• Michel MC, Korstanje C, Krauwinkel W, Cardiovascular safety of the Oral Controlled Absorption System (OCAS) formulation of tamsulosin compared to the Modified Release (MR) formulation. Eur Urol Suppl 2005;4(2):53-60
   Google Scholar
• Matsushima H, Kamimura H, Soeishi Y, Pharmacokinetics and plasma protein binding of tamsulosin hydrochloride in rats, dogs, and humans. Drug Metab Dispos 1998;26(3):240-5
   Google Scholar
• Koiso K, Akaza H, Kikuchi K, Pharmacokinetics of tamsulosin hydrochloride in patients with renal impairment: effects of alpha 1-acid glycoprotein. J Clin Pharmacol 1996;36(11):1029-38
   Google Scholar
• Soeishi Y, Matsushima H, Watanabe T, Absorption, metabolism and excretion of tamsulosin hydrochloride in man. Xenobiotica 1996;26(6):637-45
   Google Scholar
• Taguchi K, Saitoh M, Sato S, Effects of tamsulosin metabolites at alpha-1 adrenoceptor subtypes. J Pharmacol Exp Ther 1997;280(1):1-5
   Google Scholar
• Kamimura H, Oishi S, Matsushima H, Identification of cytochrome P450 isozymes involved in metabolism of the alpha1-adrenoceptor blocker tamsulosin in human liver microsomes. Xenobiotica 1998;28(10):909-22
   Google Scholar
• GlaxoSmithKline. Prescribing Information for AVODART Soft Gelatin Capsules, 0.5 mg http://us.gsk.com/products/assets/us_avodart.pdf
   Google Scholar
• Kirby RS, Roehrborn C, Boyle P, Efficacy and tolerability of doxazosin and finasteride, alone or in combination, in treatment of symptomatic benign prostatic hyperplasia: the Prospective European Doxazosin and Combination Therapy (PREDICT) trial. Urology 2003;61(1):119-26
   Google Scholar
• McConnell JD, Roehrborn CG, Bautista OM, The long-term effect of doxazosin, finasteride, and combination therapy on the clinical progression of benign prostatic hyperplasia. N Engl J Med 2003;349(25):2387-98
   Google Scholar
• Gittelman M, Ramsdell J, Young J, McNicholas T. Dutasteride improves objective and subjective disease measures in men with benign prostatic hyperplasia and modest or severe prostate enlargement. J Urol 2006;176(3):1045-50, discussion 50
   Google Scholar
• Roehrborn CG, Siami P, Barkin J, The effects of dutasteride, tamsulosin and combination therapy on lower urinary tract symptoms in men with benign prostatic hyperplasia and prostatic enlargement: 2-year results from the CombAT study. J Urol 2008;179(2):616-21, discussion 21
   Google Scholar
• Roehrborn CG, Siami P, Barkin J, The influence of baseline parameters on changes in international prostate symptom score with dutasteride, tamsulosin, and combination therapy among men with symptomatic benign prostatic hyperplasia and an enlarged prostate: 2-year data from the CombAT study. Eur Urol 2009;55(2):461-71
   Google Scholar
• Roehrborn CG, Siami P, Barkin J, The effects of combination therapy with dutasteride and tamsulosin on clinical outcomes in men with symptomatic benign prostatic hyperplasia: 4-year results from the CombAT study. Eur Urol 2010;57(1):123-31
   Google Scholar
• Montorsi F, Henkel T, Geboers A, Effect of dutasteride, tamsulosin and the combination on patient-reported quality of life and treatment satisfaction in men with moderate-to-severe benign prostatic hyperplasia: 4-year data from the CombAT study. Int J Clin Pract 2010;64(8):1042-51
   Google Scholar
• Issa MM, Runken MC, Grogg AL, Shah MB. A large retrospective analysis of acute urinary retention and prostate-related surgery in BPH patients treated with 5-alpha reductase inhibitors: dutasteride versus finasteride. Am J Manag Care 2007;13(Suppl 1):S10-16
   Google Scholar
• Fenter TC, Davis EA, Shah MB, Lin PJ. Dutasteride vs finasteride: assessment of differences in acute urinary retention rates and surgical risk outcomes in an elderly population aged ≥ 65 years. Am J Manag Care 2008;14(5 Suppl 2):S154-9
   Google Scholar
• Barkin J, Guimaraes M, Jacobi G, Alpha-blocker therapy can be withdrawn in the majority of men following initial combination therapy with the dual 5alpha-reductase inhibitor dutasteride. Eur Urol 2003;44(4):461-6
   Google Scholar
• Naslund M, Black L, Eaddy M, Batiste LR. Differences in alpha blocker usage among enlarged prostate patients receiving combination therapy with 5 ARIs. Am J Manag Care 2007;13(Suppl 1):S17-22
   Google Scholar
• Nickel JC, Sander S, Moon TD. A meta-analysis of the vascular-related safety profile and efficacy of alpha-adrenergic blockers for symptoms related to benign prostatic hyperplasia. Int J Clin Pract 2008;62(10):1547-59
   Google Scholar
• Blouin MC, Blouin J, Perreault S, Intraoperative floppy-iris syndrome associated with alpha1-adrenoreceptors: comparison of tamsulosin and alfuzosin. J Cataract Refract Surg 2007;33(7):1227-34
   Google Scholar
• Oelke M, Bachmann A, Descazeaud A, Guidelines on Conservative Treatment of Non-neurogenic Male LUTS. Available from: http://www.uroweb.org/?id=218&gid=7 [Cited 29 July 2010]
   Google Scholar
• van Dijk MM, de la Rosette JJ, Michel MC. Effects of alpha(1)-adrenoceptor antagonists on male sexual function. Drugs 2006;66(3):287-301
   Google Scholar
• Nordling J. Efficacy and safety of two doses (10 and 15 mg) of alfuzosin or tamsulosin (0.4 mg) once daily for treating symptomatic benign prostatic hyperplasia. BJU Int 2005;95(7):1006-12
   Google Scholar
• Hofner K, Claes H, De Reijke TM, Tamsulosin 0.4 mg once daily: effect on sexual function in patients with lower urinary tract symptoms suggestive of benign prostatic obstruction. Eur Urol 1999;36(4):335-41
   Google Scholar
• Djavan B, Marberger M. A meta-analysis on the efficacy and tolerability of alpha1-adrenoceptor antagonists in patients with lower urinary tract symptoms suggestive of benign prostatic obstruction. Eur Urol 1999;36(1):1-13
   Google Scholar
• Djavan B, Chapple C, Milani S, Marberger M. State of the art on the efficacy and tolerability of alpha1-adrenoceptor antagonists in patients with lower urinary tract symptoms suggestive of benign prostatic hyperplasia. Urology 2004;64(6):1081-8
   Google Scholar
• Roehrborn CG, Van Kerrebroeck P, Nordling J. Safety and efficacy of alfuzosin 10 mg once-daily in the treatment of lower urinary tract symptoms and clinical benign prostatic hyperplasia: a pooled analysis of three double-blind, placebo-controlled studies. BJU Int 2003;92(3):257-61
   Google Scholar
• Clifford GM, Farmer RD. Medical therapy for benign prostatic hyperplasia: a review of the literature. Eur Urol 2000;38(1):2-19
   Google Scholar
• Montorsi F, Moncada I. Safety and Tolerability of Treatment for BPH. Eur Urol Suppl 2006;5(20):1004-12
   Google Scholar
• Dutasteride/Tamsulosin Combination for BPH Approved in Europe http://www.gsk.com/media/pressreleases/2010/2010_pressrelease_10036.htm
   Google Scholar
• FDA approves Jalyn™, a fixed-dose combination of dutasteride and tamsulosin, for symptomatic BPH in men with an enlarged prostate http://www.drugs.com/newdrugs/fda-approves-jalyn-fixed-combination-dutasteride-tamsulosin-symptomatic-bph-men-enlarged-prostate-2183.html
   Google Scholar
• Lepor H. Long-term evaluation of tamsulosin in benign prostatic hyperplasia: placebo-controlled, double-blind extension of phase III trial. Tamsulosin Investigator Group. Urology 1998;51(6):901-6
   Google Scholar
• Lepor H. Phase III multicenter placebo-controlled study of tamsulosin in benign prostatic hyperplasia. Tamsulosin Investigator Group. Urology 1998;51(6):892-900
   Google Scholar
• Narayan P, Tewari A. A second phase III multicenter placebo controlled study of 2 dosages of modified release tamsulosin in patients with symptoms of benign prostatic hyperplasia. United States 93-01 Study Group. J Urol 1998;160(5):1701-6
   Google Scholar
• Roehrborn CG, Marks LS, Fenter T, Efficacy and safety of dutasteride in the four-year treatment of men with benign prostatic hyperplasia. Urology 2004;63(4):709-15
   Google Scholar
• Roehrborn CG, Bruskewitz R, Nickel JC, Sustained decrease in incidence of acute urinary retention and surgery with finasteride for 6 years in men with benign prostatic hyperplasia. J Urol 2004;171(3):1194-8
   Google Scholar
• Lepor H, Williford WO, Barry MJ, The efficacy of terazosin, finasteride, or both in benign prostatic hyperplasia. Veterans Affairs Cooperative Studies Benign Prostatic Hyperplasia Study Group. N Engl J Med 1996;335(8):533-9
   Google Scholar
• Debruyne FM, Jardin A, Colloi D, Sustained-release alfuzosin, finasteride and the combination of both in the treatment of benign prostatic hyperplasia. European ALFIN Study Group. Eur Urol 1998;34(3):169-75
   Google Scholar
• Kirby RS. A randomized, double-blind crossover study of tamsulosin and controlled-release doxazosin in patients with benign prostatic hyperplasia. BJU Int 2003;91(1):41-4
   Google Scholar